Day 1 ( 11.13 Wed)
12:00 – 13:00
Registration
13:00 – 13:05
Welcoming Remarks
Lisa Soyeon Park, Chairman, Prestige Biopharma Group
13:05 – 13:10
Opening Address
Sang Seok Koh, CEO, Prestige Biopharma IDC
13:10 – 13:15
Congratulatory Speech
Dong Seok Park, Director General, Busan Metropolitan City
Plenary Lecture | Chair: Tae Heung Kang (Director, Prestige Biopharma IDC)
13:15 – 14:00
BioEvolution: From Treating to Modulating Diseases
Safaraz K. Niazi, Professor, University of Illinois, USA
14:00 – 14:10
Coffee Break
Session 1. Therapeutic Opportunity | Chair: Tae Heung Kang (Director, Prestige Biopharma IDC)
14:10 – 14:30
S1-1. Korea Drug Development Fund: Business Strategy
Bok Hwan Chun, R&D Director, Korea Drug Development Fund, Korea
14:30 – 15:00
S1-2. Structure-Based Prediction of Neoantigens Using Tumor Reactive TIL Information
Yoon Joo Choi, Professor, Chonnam National University, Korea
15:00 – 15:30
S1-3. α-Synuclein Propagation in the Context of Parkinson’s Disease as a Systemic Disorder
Ayami Okuzumi, Professor, Juntendo University, Japan
15:30 – 15:50
Coffee Break
Session 2. Therapeutic Modality | Chair: Yeon Sook Lee (Director, Prestige Biopharma IDC)
15:50 – 16:20
S2-1. ADC R&D Trends, Strategies & Introducing CLDN18.2-targeting ADC by AbClick™ Pro
Tae Dong Han, CEO, Abtis, Korea
16:20 – 16:50
S2-2. Degrader-Antibody Conjugates (DACs) will Dominate the ‘ADC world’
Jin Keon Pai, Senior VP, Innocure Therapeutics, Korea
16:50 – 17:20
S2-3. CAR-T cell Immunotherapy: Barriers and Potential Solutions
Min Soo Kim, Professor, University of Rochester, USA
17:20 – 17:50
S2-4. Immune Modulation for Oncolytic Virus Therapy (mOTS-412):
US FDA phase 1 IND Approval
Tae Ho Hwang, CTO, Bionoxx, Korea
18:00 – 20:00
Welcome Reception
Day 2 ( 11.14 Thu)
Session 3. Open Innovation | Chair: Yong-Woo Kim (Head, Busan Center for Creative Economy & Innovation)
09:30 – 09:40
Introductory Session
Yong-Woo Kim, Head, Busan Center for Creative Economy & Innovation
09:40 – 10:10
S3-1. Bridging Borders: Unlock the Power of Collaboration in Biopharma
Christophe Lanneau, Director of Research and Platform, Genopole, France
10:10 – 10:40
S3-2. Startup Creation and Industrial R&D Collaboration at SingHealth,
Singapore’s Largest Public Healthcare Group
Danny Belkin, Director of SCOUT, SingHealth, Singpore
10:40 – 11:00
Coffee Break
11:00 – 11:30
S3-3. Open Innovation Strategy of Daewoong Pharmaceutical
Joon Seok Park, Head of Drug Discovery Center, Daewoong Pharmaceutical, Korea
11:30 – 12:00
S3-4. Fostering Biotech Innovation: Seoul Bio Hub’s Approach to Empowering Startups
Hak Zoo Kim, Team Leader of Cooperation Division, Seoul Bio Hub, Korea
12:00 – 12:30
Pannel Discussion
